Patient-derived colorectal cancer organoids that faithfully preserve the genetic, histopathological, and therapeutic response characteristics of human colorectal tumors, providing advanced models for translational oncology, drug discovery, and precision medicine research.
- Overview
- Details
- Advantages
- FAQs
Overview
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy worldwide and remains a leading cause of cancer-related mortality. The disease develops through a multistep process involving the accumulation of genetic and epigenetic alterations that transform normal intestinal epithelium into adenoma and eventually invasive carcinoma. Frequent driver mutations occur in APC, KRAS, TP53, SMAD4, PIK3CA, and BRAF, while a subset of tumors exhibit mismatch repair deficiency and microsatellite instability (MSI).
The biological complexity of colorectal cancer is characterized by extensive interpatient heterogeneity, dynamic clonal evolution, diverse molecular subtypes, and variable responses to chemotherapy, targeted therapies, and immunotherapies. Conventional 2D cell culture systems often fail to preserve the architectural organization, genetic diversity, and tumor-specific signaling networks observed in patient tumors.
Our human colorectal cancer organoids are established from primary patient tumor tissues and retain the histological architecture, genomic landscape, and functional characteristics of the original malignancies. These three-dimensional models provide a clinically relevant platform for studying colorectal tumorigenesis, validating therapeutic targets, evaluating treatment efficacy, and supporting precision oncology research.
What Pathological Features Do Colorectal Cancer Organoids Recapitulate?
- Adenoma-to-carcinoma progression-associated molecular alterations
- Aberrant Wnt/β-catenin signaling resulting from APC pathway dysregulation
- KRAS-, BRAF-, EGFR-, and PI3K-driven oncogenic signaling networks
- Microsatellite instability (MSI) and mismatch repair deficiency phenotypes
- Cancer stem cell populations expressing LGR5, CD44, and PROM1
- Tumor glandular architecture characteristic of colorectal adenocarcinoma
- Patient-specific therapeutic sensitivity and resistance profiles
- Molecular heterogeneity associated with Consensus Molecular Subtypes (CMS)
These disease-relevant features make colorectal cancer organoids highly valuable for modeling CRC biology, identifying predictive biomarkers, and developing next-generation therapeutic strategies.
Fig. 1. Establishment and Applications of Human Colon Tumor Organoids (Heydari Z, et al., 2025).
Our Colorectal Cancer Organoids
Our colorectal cancer organoids are high-quality, ready-to-use human tumor models developed under optimized culture conditions to preserve clinically relevant disease phenotypes while supporting reproducibility and scalability.
Disease-Relevant Features
- High fidelity to patient-derived colorectal tumors with preservation of disease-relevant phenotypes
- Tumor heterogeneity maintained through diverse cellular populations and cancer stem cell compartments
- Genetically representative models carrying common CRC-associated mutations and pathway alterations
- Predictive therapeutic responses suitable for efficacy and resistance studies
- Ready-to-use cryopreserved format enabling rapid experimental deployment
Characterization & Validation
Our colorectal cancer organoids undergo comprehensive disease phenotype validation to ensure biological relevance and experimental reproducibility.
- Genetic characterization: Analysis of clinically relevant mutations including APC, KRAS, TP53, and BRAF
- Tumor biomarker expression: Validation of EPCAM, CK20, CDX2, LGR5, and additional CRC-associated markers
- 3D tumor morphology: Preservation of glandular architecture and patient-like tumor organization
- Disease phenotype assessment: Evaluation of proliferation, pathway activation, and therapeutic response profiles
- Quality control: Post-thaw viability ≥85%, identity verification, low batch variability, and mycoplasma-free status
Applications
Our ready-to-use colorectal cancer organoids provide a powerful platform for a broad range of cancer research applications:
- Disease Mechanism Studies: Investigate tumor initiation, progression, metastasis, and cancer stem cell biology.
- Drug Discovery & Screening: Evaluate small molecules, targeted therapies, biologics, and combination treatment strategies.
- Precision Oncology: Assess patient-specific therapeutic responses and support personalized treatment development.
- Resistance Mechanism Research: Explore intrinsic and acquired resistance to chemotherapy, targeted therapies, and immunotherapies.
- Target Validation: Identify and validate novel therapeutic targets using human-relevant tumor models.
Why Choose Our Colorectal Cancer Organoids
- More predictive than conventional 2D cancer models for evaluating therapeutic efficacy and resistance
- Disease-relevant organoids that preserve clinically important tumor phenotypes and molecular characteristics
- Ready-to-use, eliminating lengthy tumor model establishment procedures
- Reproducible, supported by rigorous quality control and batch consistency testing
- HTS-compatible, enabling scalable drug screening and therapeutic evaluation workflows
FAQs
Q: What disease phenotypes are validated in your colorectal cancer organoids?
Our organoids are validated for clinically relevant tumor characteristics including genetic alterations, tumor biomarker expression, cancer stem cell populations, pathway activation, and disease-specific therapeutic responses.
Q: Do the organoids retain tumor heterogeneity after cryopreservation?
Yes. Our optimized cryopreservation and recovery protocols are designed to maintain key cellular populations and disease-relevant phenotypes following thawing.
Q: What downstream assays can be performed using these organoids?
These organoids support a wide range of assays including viability testing, immunofluorescence staining, high-content imaging, qPCR, RNA sequencing, pathway analysis, and drug response studies.
Q: Can customized colorectal cancer organoid models be generated?
Yes. We can support customized projects involving specific genetic backgrounds, patient-derived samples, and tailored disease modeling applications depending on research requirements.
Accelerate colorectal cancer research with physiologically relevant, ready-to-use human tumor organoids.
Contact us today to request detailed characterization data, pricing information, or customized colorectal cancer organoid solutions tailored to your research objectives.
Online Inquiry